메뉴 건너뛰기




Volumn 82, Issue , 2015, Pages eS9-eS16

Canakinumab for the Patient With Difficult-to-Treat Gouty Arthritis: Review of the Clinical Evidence

Author keywords

Anti IL 1 therapy; Canakinumab; Gouty arthritis; Triamcinolone acetonide; RELIEVED; RELIEVED II

Indexed keywords

CANAKINUMAB; COLCHICINE; TRIAMCINOLONE ACETONIDE; ANTIGOUT AGENT; GLUCOCORTICOID; INTERLEUKIN 1BETA; MONOCLONAL ANTIBODY; NONSTEROID ANTIINFLAMMATORY AGENT;

EID: 84955290033     PISSN: 1297319X     EISSN: 17787254     Source Type: Journal    
DOI: 10.1016/S1297-319X(15)30003-8     Document Type: Article
Times cited : (11)

References (27)
  • 1
    • 54249085533 scopus 로고    scopus 로고
    • Developments in the scientific and clinical understanding of gout
    • So A Developments in the scientific and clinical understanding of gout. Arthritis Res Ther 2008, 10:221.
    • (2008) Arthritis Res Ther , vol.10 , pp. 221
    • So, A.1
  • 3
    • 79551559557 scopus 로고    scopus 로고
    • Gout
    • Neogi T Gout. N Engl J Med 2011, 64:443-452.
    • (2011) N Engl J Med , vol.64 , pp. 443-452
    • Neogi, T.1
  • 4
    • 84867405545 scopus 로고    scopus 로고
    • Canakinumab for acute gouty arthritis in patients with limited treatment options: results from two randomised, multicentre, active-controlled, double-blind trials and their initial extensions
    • Schlesinger N, Alten RE, Bardin T, et al. Canakinumab for acute gouty arthritis in patients with limited treatment options: results from two randomised, multicentre, active-controlled, double-blind trials and their initial extensions. Ann Rheum Dis 2012, 71:1839-1848.
    • (2012) Ann Rheum Dis , vol.71 , pp. 1839-1848
    • Schlesinger, N.1    Alten, R.E.2    Bardin, T.3
  • 5
    • 67449099218 scopus 로고    scopus 로고
    • Quality of life and disability in patients with treatment-failure gout
    • Becker MA, Schumacher HR, Benjamin KL, et al. Quality of life and disability in patients with treatment-failure gout. J Rheumatol 2009, 36:1041-1048.
    • (2009) J Rheumatol , vol.36 , pp. 1041-1048
    • Becker, M.A.1    Schumacher, H.R.2    Benjamin, K.L.3
  • 6
    • 65249136104 scopus 로고    scopus 로고
    • Perceptions of disease and health-related quality of life among patients with gout
    • Lee SJ, Hirsch JD, Terkeltaub R, et al. Perceptions of disease and health-related quality of life among patients with gout. Rheumatology 2009, 48:582-586.
    • (2009) Rheumatology , vol.48 , pp. 582-586
    • Lee, S.J.1    Hirsch, J.D.2    Terkeltaub, R.3
  • 7
    • 84869180170 scopus 로고    scopus 로고
    • 2012 American College of Rheumatology Guidelines for Management of Gout. Part 2: Therapy and antiinflammatory prophylaxis of acute gouty arthritis
    • Khanna D, Khanna PP, Fitzgerald JD, et al. 2012 American College of Rheumatology Guidelines for Management of Gout. Part 2: Therapy and antiinflammatory prophylaxis of acute gouty arthritis. Arthritis Care Res 2012, 64:1447-1461.
    • (2012) Arthritis Care Res , vol.64 , pp. 1447-1461
    • Khanna, D.1    Khanna, P.P.2    Fitzgerald, J.D.3
  • 8
    • 79551674574 scopus 로고    scopus 로고
    • Prevalence of contraindications and prescription of pharmacologic therapies for gout
    • Keenan RT, O'Brien WR, Lee KH, et al. Prevalence of contraindications and prescription of pharmacologic therapies for gout. Am J Med 2011, 124:155-163.
    • (2011) Am J Med , vol.124 , pp. 155-163
    • Keenan, R.T.1    O'Brien, W.R.2    Lee, K.H.3
  • 9
    • 77957688721 scopus 로고    scopus 로고
    • Canakimuab for the treatment of acute flares in difficult-to-treat gouty arthritis: results of a multicenter, phase II, dose-ranging study
    • So A, Meulemeester M Pikhlak A, et al. Canakimuab for the treatment of acute flares in difficult-to-treat gouty arthritis: results of a multicenter, phase II, dose-ranging study. Arthritis Rheum 2010, 62:3064-3076.
    • (2010) Arthritis Rheum , vol.62 , pp. 3064-3076
    • So, A.1    Meulemeester, M.2    Pikhlak, A.3
  • 11
    • 34548142983 scopus 로고    scopus 로고
    • Independent impact of gout on mortality and risk for coronary heart disease
    • Choi HK, Curhan G Independent impact of gout on mortality and risk for coronary heart disease. Circulation 2007, 116:894-900.
    • (2007) Circulation , vol.116 , pp. 894-900
    • Choi, H.K.1    Curhan, G.2
  • 12
    • 33846998296 scopus 로고    scopus 로고
    • Prevalence of the metabolic syndrome in patients with gout: the Third National Health and Nutrition Examination Survey
    • Choi HK, Ford ES, Li C, Curhan G Prevalence of the metabolic syndrome in patients with gout: the Third National Health and Nutrition Examination Survey. Arthritis Rheum 2007, 57:109-115.
    • (2007) Arthritis Rheum , vol.57 , pp. 109-115
    • Choi, H.K.1    Ford, E.S.2    Li, C.3    Curhan, G.4
  • 13
    • 52949131004 scopus 로고    scopus 로고
    • Gout and the risk of type 2 diabetes among men with a high cardiovascular risk profile
    • Choi H, Vera M, Krishman E Gout and the risk of type 2 diabetes among men with a high cardiovascular risk profile. Rheumatology 2008, 47:1567-1570.
    • (2008) Rheumatology , vol.47 , pp. 1567-1570
    • Choi, H.1    Vera, M.2    Krishman, E.3
  • 14
    • 56649112606 scopus 로고    scopus 로고
    • Cardiovascular disease risk factor assessment and management in gout: an analysis using guideline-based electronic clinical decision support
    • Colvine K, Kerr AJ, McLachlan A, et al. Cardiovascular disease risk factor assessment and management in gout: an analysis using guideline-based electronic clinical decision support. N Z Med J 2008, 121:73-81.
    • (2008) N Z Med J , vol.121 , pp. 73-81
    • Colvine, K.1    Kerr, A.J.2    McLachlan, A.3
  • 15
    • 55249099579 scopus 로고    scopus 로고
    • The role of hyperuricemia and gout in kidney and cardiovascular disease
    • Edwards NL The role of hyperuricemia and gout in kidney and cardiovascular disease. Cleve Clin J Med 2008, 75 (suppl 5):S13-S16.
    • (2008) Cleve Clin J Med , pp. S13-S16
    • Edwards, N.L.1
  • 16
    • 32944468985 scopus 로고    scopus 로고
    • Gout-associated uric acid crystals activate the NALP3 inflammasome
    • Martinon F, Petrilli V, Mayor A, et al. Gout-associated uric acid crystals activate the NALP3 inflammasome. Nature 2006, 440:237-241.
    • (2006) Nature , vol.440 , pp. 237-241
    • Martinon, F.1    Petrilli, V.2    Mayor, A.3
  • 17
    • 78149484804 scopus 로고    scopus 로고
    • The pathogenesis of bone erosions in gouty arthritis
    • Schlesinger N, Thiele RG The pathogenesis of bone erosions in gouty arthritis. Ann Rheum Dis 2010, 69:1907-1912.
    • (2010) Ann Rheum Dis , vol.69 , pp. 1907-1912
    • Schlesinger, N.1    Thiele, R.G.2
  • 18
    • 18644374105 scopus 로고    scopus 로고
    • Blocking IL-1 in systemic inflammation
    • Dinarello CA Blocking IL-1 in systemic inflammation. J Exp Med 2005, 201:1355-1359.
    • (2005) J Exp Med , vol.201 , pp. 1355-1359
    • Dinarello, C.A.1
  • 19
    • 66049094734 scopus 로고    scopus 로고
    • In vivo regulation of interleukin 1beta in patients with cryopyrin-associated periodic syndromes
    • Lachmann HJ, Lowe P, Felix SD, et al. In vivo regulation of interleukin 1beta in patients with cryopyrin-associated periodic syndromes. J Exp Med 2009, 206:1029-1036.
    • (2009) J Exp Med , vol.206 , pp. 1029-1036
    • Lachmann, H.J.1    Lowe, P.2    Felix, S.D.3
  • 20
    • 46149100545 scopus 로고    scopus 로고
    • The human anti-IL-1 beta monoclonal antibody ACZ885 is effective in joint inflammation models in mice and in a proof-of-concept study in patients with rheumatoid arthritis
    • Alten R, Gram H, Joosten LA, et al. The human anti-IL-1 beta monoclonal antibody ACZ885 is effective in joint inflammation models in mice and in a proof-of-concept study in patients with rheumatoid arthritis. Arthritis Res Ther 2008, 10:R67.
    • (2008) Arthritis Res Ther , vol.10 , pp. R67
    • Alten, R.1    Gram, H.2    Joosten, L.A.3
  • 21
    • 84955324434 scopus 로고    scopus 로고
    • Ilaris (canakinumab) Summary of Product Characteristics. Novartis Europharm Ltd, 2014.
    • (2014)
  • 22
    • 0017483654 scopus 로고
    • Preliminary criteria for the classification of the acute arthritis of primary gout
    • Wallace SL, Robinson H, Masi AT, et al. Preliminary criteria for the classification of the acute arthritis of primary gout. Arthritis Rheum 1977, 20:895-900.
    • (1977) Arthritis Rheum , vol.20 , pp. 895-900
    • Wallace, S.L.1    Robinson, H.2    Masi, A.T.3
  • 23
    • 84955245569 scopus 로고    scopus 로고
    • Novartis Pharma AG, data on file.
    • Novartis Pharma AG, data on file.
  • 24
    • 84955292709 scopus 로고    scopus 로고
    • Efficacy and safety of canakinumab versus triamcinolone acetonide in patients with gouty arthritis unable to use non-steroidal anti-inflammatory drugs and colchicine, and on stable urate-lowering therapy or unable to use urate-lowering therapy
    • Bardin T, So A, Alten R, et al. Efficacy and safety of canakinumab versus triamcinolone acetonide in patients with gouty arthritis unable to use non-steroidal anti-inflammatory drugs and colchicine, and on stable urate-lowering therapy or unable to use urate-lowering therapy. Arthritis Rheum 2012, 64(suppl):S811.
    • (2012) Arthritis Rheum , vol.64 , pp. S811
    • Bardin, T.1    So, A.2    Alten, R.3
  • 25
    • 84955293508 scopus 로고    scopus 로고
    • Long-term safety and efficacy of canakinumab vs triamcinolone acetonide in patients with frequent acute gouty arthritis attacks who are contraindicated, intolerant or unresponsive to NSAIDs and/or colchicine
    • Alten R, Schlesinger N, So A, et al. Long-term safety and efficacy of canakinumab vs triamcinolone acetonide in patients with frequent acute gouty arthritis attacks who are contraindicated, intolerant or unresponsive to NSAIDs and/or colchicine. Ann Rheum Dis 2014, 73(suppl 2):785.
    • (2014) Ann Rheum Dis , vol.73 , pp. 785
    • Alten, R.1    Schlesinger, N.2    So, A.3
  • 26
    • 84955298680 scopus 로고    scopus 로고
    • Canakinumab in frequently flaring gouty arthritis patients, contraindicated, intolerant or unresponsive to NSAIDs and/or colchicine: safety and efficacy results from long-term follow-up
    • Schlesinger N, Alten R, Bardin T, et al. Canakinumab in frequently flaring gouty arthritis patients, contraindicated, intolerant or unresponsive to NSAIDs and/or colchicine: safety and efficacy results from long-term follow-up. Arthritis Rheum 2014, 66(suppl):S66.
    • (2014) Arthritis Rheum , vol.66 , pp. S66
    • Schlesinger, N.1    Alten, R.2    Bardin, T.3
  • 27
    • 79953094557 scopus 로고    scopus 로고
    • Canakinumab relieves symptoms of acute flares and improves health-related quality of life in patients with difficult-to-treat gouty arthritis by suppressing inflammation: results of a randomized, dose-ranging study
    • Schlesinger N, De Meulemeester MD, Pikhlak A, et al. Canakinumab relieves symptoms of acute flares and improves health-related quality of life in patients with difficult-to-treat gouty arthritis by suppressing inflammation: results of a randomized, dose-ranging study. Arthritis Res Ther 2011, 13:R53.
    • (2011) Arthritis Res Ther , vol.13 , pp. R53
    • Schlesinger, N.1    De Meulemeester, M.D.2    Pikhlak, A.3


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.